ArticlePediatric cardiology2026
Access to Care and Therapy for Kawasaki Disease in Morocco: A Kawasaki Disease Arab Initiative (Kawarabi) Multicenter Survey.
Article in Pediatric cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Kawasaki disease (KD) is a childhood vasculitis with common pediatric ailments features. The KD coronary tropism and delayed diagnosis lead to long-term consequences. A 42-question web-based survey, developed in collaboration with the KD Arab Initiative (Kawarabi), covered pediatricians in charge of KD across major Moroccan cities. Responses from 18/23 (78%) contacts covered 12 universities and 2 public health hospitals, and 4 private practices. Main responders (9 pediatricians, 3 pediatric cardiologists, 2 pediatric and adult cardiologists, and 2 pediatric rheumatologists) follow the European (55.6%), the American (27.8%) guidelines, or local consensus recommendations (16.6%). First-line treatment was intravenous immunoglobulin (88.8%), or corticosteroids (5.5%) or acetyl salicylic acid (5.5%) monotherapy. On a scale from 1 to 10, KD knowledge was rated high (5 to 8) among the medical community, but low (1 to 4) in the general population. There was inequity in access to care and treatment options, varying from almost impossible to excellent. Post-discharge follow-up was carried out by pediatricians (77.7%), with access to pediatric cardiology (61.1%). Anticoagulation was available (88.8%) using anti-vitamin K or low-molecular-weight-heparin. A 10-year expert opinion estimate of KD shock syndrome, giant coronary aneurysms, myocardial ischemia or acute coronary syndrome, and coronary artery bypass grafts, totaled 62, 74, 13, and 9, respectively. KD remains a challenge in Morocco despite dedicated professionals. National seminars and collaborative research initiatives can be optimized with international engagements. Adherence to standardized diagnostic and treatment protocols, making intravenous immunoglobulin availability a national priority requires partnership with government agencies and healthcare officials.
Indexed as
Identifiers
41553482What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.